Dr Landgren on the Utility of Tocilizumab Prophylaxis in Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD, professor of medicine, chief, Division of Myeloma, Department of Medicine, University of Miami, Miller School of Medicine; director, Sylvester Myeloma Institute; co-leader, Translational and Clinical Oncology Program, Paul J. DiMare Endowed Chair in Immunotherapy, Sylvester Comprehensive Cancer Center, discusses an investigation of tocilizumab (Actemra) prophylaxis in patients with relapsed or refractory multiple myeloma treated with teclistamab-cqyv (Tecvayli), elranatamab-bcmm (Elrexfio), or talquetamab-tgvs (Talvey).